GlassScriptPhysician profile
Kimberley Celeste Palm
NPI 1144791757
$3,198.34
in general payments reported to CMS, 2019-2025
24 companies · $656 in 2025
The $656 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $171 · 2022: $340 · 2023: $897 · 2024: $1,135 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,687.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $538.39 | 2022-2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $532.72 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $331.38 | 2021-2025 | Farxiga |
| Pfizer INC. | $202.94 | 2024-2025 | |
| Edwards Lifesciences Corporation | $188.74 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Janssen Pharmaceuticals, INC | $157.55 | 2022-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.78 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $149.99 | 2022-2025 | Lifevest |
| Amgen INC. | $132.24 | 2023-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $115.87 | 2023-2025 | Synergy, Watchman |
| Lantheus Medical Imaging, INC. | $106.55 | 2022-2023 | Definity |
| Novartis Pharmaceuticals Corporation | $85.65 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $83.13 | 2023-2024 | Inpefa |
| Chiesi USA, INC. | $72.32 | 2022 | |
| Merck Sharp & Dohme LLC | $62.54 | 2022-2023 | Verquvo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $54.75 | 2023 | Linq II |
| Esperion Therapeutics, INC. | $46.62 | 2024-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $44.10 | 2025 | |
| Sanofi-Aventis U.S. LLC | $43.46 | 2024 | |
| Novo Nordisk INC | $21.93 | 2025 | Wegovy |
| Philips North America LLC | $21.62 | 2024 | (5091) Amb Mon & Diag Und |
| Irhythm Technologies, INC. | $18.55 | 2023 | Zio Xt Patch |
| Bard Peripheral Vascular, INC. | $17.28 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $15.24 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberley Palm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.